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Abstract The objectives of this study were to determine whether
leptin synthesis is regulated by the sympathetic nervous system
and if so whether L-adrenergic receptors mediate this effect. We
show that sympathetic blockade by reserpine increases leptin
mRNA levels in brown but not white adipose tissue, while acute
cold-exposure decreases leptin expression 10-fold in brown
adipose tissue and 2-fold in white adipose tissue. The cold-
induced reduction in leptin mRNA can be prevented by a
combination of propranolol and SR 59230A but not by either
antagonist alone, indicating that L3-adrenergic receptors and
classical L1/L2-adrenergic receptors both mediate responses to
sympathetic stimulation. Circulating leptin levels reflect synthe-
sis in white adipose tissue but not in brown adipose tissue.
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1. Introduction
Obesity results from a chronic disequilibrium between ca-
loric intake and energy expenditure, and is associated with an
increased risk for diabetes and cardiovascular disorders. En-
ergy expenditure is determined partly by activity and exercise,
and partly by adaptive thermogenesis. This process is driven
by the sympathetic nervous system (SNS) and occurs in tissues
expressing uncoupling proteins (UCP-1,-2 and -3), including
brown adipose tissue (BAT) and skeletal muscle. One media-
tor of thermogenesis is the hormone leptin, which plays a
critical role in energy balance by reducing food intake as
well as increasing energy expenditure [1]. Leptin infusion has
been shown to increase expression of UCP-1 in BAT, but only
in the presence of an intact sympathetic innervation [2]. Lep-
tin has also been shown directly to increase sympathetic nerve
activity in BAT and other regions including rat hindlimb [3].
Leptin is synthesised primarily in white adipose tissue
(WAT), and to a lesser extent in BAT [4,5]. The synthesis
of leptin is regulated by both chronic and acute stimuli. Obese
animals and humans have high levels of leptin mRNA and
circulating leptin, due to stimulation of leptin expression with
increasing size of white adipocytes [6]. In the short term how-
ever, leptin mRNA is modulated by feeding status, plasma
insulin and corticosteroid levels [7,8]. There is considerable
evidence that a negative feedback loop involving the sympa-
thetic nervous system also regulates leptin synthesis. When the
SNS is stimulated by acute cold-exposure, a substantial reduc-
tion in leptin mRNA has been observed in both WAT [9] and
BAT [10]. Conversely, blockade of noradrenaline synthesis by
K-methyl-p-tyrosine has been shown recently to cause marked
increases in WAT leptin mRNA and also plasma leptin [11].
The e¡ect of cold-exposure can be mimicked by treatment of
animals with L-adrenoceptor (AR) agonists [9,10,12,13]. This
is a direct e¡ect on adipocytes, as the suppression of leptin
synthesis by L-AR agonists is seen in isolated brown [5] and
white adipocytes [14,15]. Inhibition of leptin expression also
occurs following treatment of cells with cyclic AMP (cAMP)
analogues and forskolin, indicating involvement of the cAMP/
protein kinase A signalling pathway [5,14,16].
It is widely supposed that the L3-AR mediates the e¡ect of
the SNS on leptin expression [5,11,13,14,17]. The present
study describes the e¡ects of modulating SNS activity on
the expression of leptin mRNA in WAT and BAT and on
levels of circulating leptin. Using the antagonists propranolol
and SR 59230A [18], we show that L3-ARs are not solely
responsible for mediating the e¡ects of endogenous sympa-
thetic stimulation, with L1/L2-ARs also playing an important
role.
2. Methods
2.1. Animals and treatments
All animals used were 8 weeks old male C57BL/6J lean (+/+) mice.
Mice had continuous access to tap water and a standard rodent diet
containing 20%(w/w) protein and 3%(w/w) fat. Mice were anaesthe-
tised by 80% CO2/20% O2 and killed by decapitation (according to
guidelines produced by the Monash University Animal Experimenta-
tion Ethics Committee). Blood was collected into tubes containing
50 U heparin, and plasma was harvested by centrifugation and stored
at 370‡C until analysis. Circulating leptin was measured by a com-
mercial leptin RIA kit (Linco Research, St. Charles, MO, USA) with
a limit of sensitivity of 0.2 ng/ml. Epididymal WAT and interscapular
BAT, carefully freed from surrounding WAT, were dissected and
stored at 370‡C until analysis.
Reserpine was used to investigate the e¡ects of sympathetic block-
ade. Reserpine was dissolved in 20% ascorbic acid solution, the 20%
ascorbic acid alone being administered i.p. to control animals. Treated
mice received 2 mg/kg i.p. at time 0, with a second dose of 2 mg/kg
i.p. at 20 h. The mice were killed 24 h after the second injection. To
investigate the e¡ects of acute cold-exposure, mice were housed indi-
vidually in empty plastic cages and placed in a cold room at 4‡C for
4 h. Control animals remained at room temperature (22‡C). The ef-
fects of L-AR antagonists were also investigated by injecting 1.5 mg/
kg SR-59230A i.p., 1.5 mg/kg (3)-propranolol i.p. or both antagonists
together at room temperature 15 min before the mice were placed at
4‡C or left at 22‡C for 4 h. Both the SR-59230A and (3)-propranolol
were dissolved in 5%(v/v) dimethyl sulphoxide/2.5%(v/v) ethanol. This
solvent (0.1 ml) was administered i.p. to control mice.
2.2. Preparation of RNA
RNA was isolated from tissues using a procedure based on that of
Chomczynski and Sacchi [19]. Frozen tissue was ground to a ¢ne
powder in a stainless steel mortar and pestle pre-cooled in liquid
nitrogen. Total RNA was extracted by homogenising in TRIZOL
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according to the manufacturer’s instructions. To avoid cross-contam-
ination, the homogeniser probe was dismantled and washed thor-
oughly between each sample. The yield and quality of the RNA
were assessed by measuring absorbance at 260 and 280 nm, and by
electrophoresis on 1.2% agarose gels.
2.3. Reverse transcription (RT)
cDNAs were synthesised by diluting 1 Wg of total RNA to 7.7 Wl
with sterilised distilled water, heating to 70‡C for 5 min and placing
on ice 2 min prior to the addition of reaction mixture containing
1xRT bu¡er (10 mM Tris pH 9.0, 50 mM KCl, 0.1% Triton
X-100), 1 mM dNTPs, 5 mM MgCl2, 20 U RNasin, 20 U AMV
reverse transcriptase and 50 Wg/ml oligo(dT)15 in a volume of
12.3 Wl. Following brief centrifugation, the reactions were incubated
at 42‡C for 45 min and then at 95‡C for 3 min. The cDNAs were then
cooled on ice before addition of 1 mM EDTA (20 Wl) and stored at
370‡C without further treatment.
2.4. Polymerase chain reaction (PCR)
PCR ampli¢cation was carried out on cDNA equivalent to 100 ng
of starting RNA, using separately oligonucleotide primers speci¢c for
mouse leptin (forward 5P GATGACACCAAAACCCTCATCAAG 3P,
and reverse 5P GCCACCACCTCTGTGGAGTAG 3P) and L-actin
(forward 5P ATCCTGCGTCTGGACCTGGCTG 3P, and reverse 5P
CCTGCTTGCTGATCCACATCTGCTG 3P). The actin reverse prim-
er was labelled prior to PCR by mixing 625 ng oligonucleotide, 1U
One-Phor-All Plus bu¡er (10 mM Tris-acetate pH 7.5, 10 mM
Mg(OAc)2, 50 mM KOAc), 100 WCi [Q-33P]-ATP (2000 Ci/mmol)
and 28.5 U T4 polynucleotide kinase in a ¢nal volume of 50 Wl.
This reaction was incubated at 37‡C for 30 min and then at 95‡C
for 5 min. End-labelled primer was stored at 320‡C. PCR mixes
contained cDNA, 1 U of Taq polymerase, 1UPCR bu¡er (20 mM
Tris-HCl pH 8.4, 50 mM KCl), 200 WM dNTPs, 2 mM Mg(OAc)2
(leptin) or 1 mM Mg(OAc)2 (actin), 25 ng (leptin) or 12.5 ng (actin) of
forward primer and 25 ng of reverse primer (leptin) or 12.5 ng end-
labelled reverse primer (actin) in a volume of 10 Wl. For each set of
tissues (eg. all samples of WAT), a single leptin or actin reaction mix
containing all components except the cDNA was prepared for the
entire PCR experiment and aliquotted to minimise variation between
samples. Each PCR experiment included a negative control consisting
of an RT reaction containing no added RNA. PCR was carried out in
an FTS-1 capillary thermal sequencer (Corbett Research, Lidcombe,
N.S.W). Following initial denaturation of samples by heating at 95‡C
for 2 min, each cycle of ampli¢cation consisted of a stage of denatu-
ration (95‡C, 30 s), annealing (56‡C for leptin or 64‡C for actin, 30 s)
and an extension stage (72‡C, 30 s). A ¢nal extension stage was 72‡C
for 3 min.
2.5. Detection and quantitation of PCR products
PCR products corresponding to RNA samples from treated and
control mice within a given experiment were electrophoresed on the
same 1.3% agarose gel and transferred onto a Hybond N nylon
membrane by Southern blotting in 0.4 M NaOH/1 M NaCl. Mem-
branes were rinsed for 5 min in 0.5 M Tris-HCl (pH 7.5)/1 M NaCl,
then in 2USSC (0.3 M NaCl/30 mM sodium citrate). Following
transfer of [33P]-labelled actin PCR products, nylon membranes
were dried at room temperature for 30 min, then apposed directly
to phosphorimager (PI) plates. The identity of the unlabelled leptin
PCR products was veri¢ed by hybridisation to an independent probe
(5P GGCTTGGACTTCATTCCTGGGCT 3P) end-labelled in a 20 Wl
reaction mix containing 50 ng oligonucleotide, 50 WCi [Q-33P]ATP,
1UOne-Phor-All Plus bu¡er and 9.5 U T4 polynucleotide kinase.
The reaction was incubated at 37‡C for 30 min, then at 95‡C for
5 min before being diluted to 60 Wl with sterilised distilled water.
The labelled probe was separated from unincorporated nucleotide
by centrifugation through Chroma-spin 10 columns (Clontech) ac-
cording to the manufacturer’s instructions. Leptin PCR products
were ¢xed to nylon membranes by exposure to u.v.-light for 2 min
before pre-hybridisation at 42‡C for 4 h in a bu¡er containing
5USSC, 0.5% SDS, 100 Wg/ml salmon sperm DNA (pre-heated to
95‡C for 5 min), 5UDenhardts solution (1 mg/ml ¢coll type 400,
1 mg/ml polyvinylpyrrolidone, 1 mg/ml bovine serum albumin) and
0.1 mM ATP. After addition of the end-labelled oligonucleotide probe
(equivalent to 25 ng), hybridisation was performed at 42‡C for 16 h.
The ¢lters were washed in 2USSC/0.1% SDS for 30 min at 30‡C, then
for 5 min at 37‡C. Radioactivity was detected with a Molecular Dy-
namics Phosphorimager (SI) after exposure to imaging plates.
2.6. Statistical analysis
Leptin mRNA levels were corrected for any di¡erences in input
RNA by dividing the number of leptin PI units by the number of
actin PI units for each cDNA. Results are expressed as mean þ S.E.M.
For Southern blot data the mean value for control mice is expressed
as 100% (unless otherwise stated). The statistical signi¢cance of di¡er-
ences between groups was assessed using a two-tailed Student’s un-
paired t-test. Probability (P) values equal to or less than 0.05 were
considered signi¢cant. To correct for heterogeneous variance (assessed
by the F-test), Welch’s correction was applied.
2.7. Drugs and reagents
Heparin (CSL, Parkville, Vic., Australia); Reserpine, (S)-(3)-pro-
pranolol hydrochloride, SR-59230A (gift from Sano¢ Recherche,
Italy); TRIZOL reagent, oligo(dT)15, oligonucleotide primers, Taq
polymerase, 10UPCR bu¡er, salmon sperm DNA (Gibco BRL, Gai-
thersburg, USA); RNasin, 10URT bu¡er, AMV reverse transcriptase
(Promega, Annandale, N.S.W., Australia); dNTPs (100 mM each
nucleotide), 100 bp DNA ladder, One-Phor-All Plus bu¡er, T4 poly-
nucleotide kinase (Pharmacia Biotech, Sydney, N.S.W., Australia);
[Q-33P]ATP (2000 Ci/mmol: Bresatec, Adelaide, S.A., Australia).
3. Results
3.1. Determination of leptin mRNA levels in mouse tissues by
semi-quantitative PCR
The RT-PCR technique used to compare leptin mRNA
levels in mouse tissues was validated as described by Evans
et al. [20]. PCR was carried out using unlabelled primers and
following electrophoresis, PCR products were hybridised with
an independent leptin probe (see Fig. 1). Products detected in
BAT and WAT were consistent with the expected size of 353
bp. As we used intron-spanning primers, any product derived
from contaminating genomic DNA would be 2.1 kb. By doing
PCR at di¡erent cycle numbers [18,20,22] on WAT and BAT
cDNAs equivalent to a set amount of starting total RNA (100
ng), we found that the level of leptin mRNA in BAT is only
2.7% of that in WAT (S.E.M. 0.5%, n = 4). Because of this
large di¡erence in abundance, we used 22 cycles for WAT and
28 cycles for BAT in all subsequent experiments. For RT-
PCR on 100 ng RNA, these cycle numbers were within the
range where a plot of log10 PCR product versus PCR cycles
was linear [20]. We also veri¢ed that at 22 cycles, 100 ng of
WAT RNA was within the linear range of a plot of leptin
PCR product versus amount of input RNA [20].
3.2. E¡ect of sympathetic blockade on leptin mRNA and on
circulating leptin
Treatment with reserpine produced the expected symptoms
such as ptosis and diarrhoea [21]. Fig. 1 displays a Southern
blot of leptin and actin PCR products corresponding to WAT
and BAT of control mice and of mice treated with reserpine.
Fig. 2 shows that reserpine treatment did not signi¢cantly
alter leptin mRNA abundance in WAT (P = 0.14) but in-
creased the level of leptin mRNA in BAT by 3.7-fold
(P = 0.002). Despite this large increase in leptin mRNA in
BAT, reserpine treatment did not signi¢cantly a¡ect circulat-
ing leptin levels (P = 0.37).
3.3. E¡ect of cold-exposure in the absence and presence of
L-AR antagonists
The e¡ect of stimulating the SNS was tested by exposing
mice to 4‡C for 4 h. Levels of leptin mRNA in BAT decreased
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to 12% of those in control mice maintained at room temper-
ature (P = 0.008, Fig. 3). In WAT there was a smaller decrease
to 44% (P = 0.006) of the level in control mice. Serum leptin in
the cold-exposed mice was reduced to 70% (P = 0.02). To as-
sess the role of L3-ARs versus classical L1- and L2-ARs in
mediating the reduction in leptin mRNA, we treated mice
15 min prior to cold-exposure with either propranolol (a L1-
and L2-AR antagonist), SR 59230A (a selective L3-AR antag-
onist), or a combination of both drugs. A second group of
mice were treated with the antagonists but left at room tem-
perature for 4 h. As shown in Fig. 3, both propranolol and
SR 59230A produced substantial increases in BAT leptin
mRNA, to 218% (P = 0.015) and 306% (P = 0.018) respec-
tively, even when mice were maintained at room temperature.
The combination of propranolol and SR 59230A had an ad-
ditive e¡ect, increasing leptin mRNA to 495% of that in ve-
hicle-treated mice (P = 0.02). Di¡erent e¡ects were obtained
when the mice were cold-exposed following antagonist treat-
ment. Under these conditions of high SNS activity, blockade
by either antagonist alone was not su⁄cient to prevent the
large decrease in leptin mRNA (Fig. 3). In the presence of
both propranolol and SR 59230A on the other hand, cold-
exposed mice showed no signi¢cant reduction in BAT leptin
mRNA (P = 0.68).
In the WAT of mice held at room temperature, leptin
mRNA levels were not a¡ected by treatment with propranolol
or SR 59230A alone, but were increased to 176% in mice
treated with the combination of antagonists compared to ve-
hicle (P = 0.02, Fig. 3). In cold-exposed mice, treatment with
propranolol or SR 59230A alone produced a slight but non-
signi¢cant increase in leptin mRNA relative to cold-exposed
mice treated with vehicle (P = 0.28 and 0.057 respectively).
Again the combination of propranolol and SR 59230A pre-
vented the cold-induced decrease in leptin mRNA (P = 0.57).
The results seen in WAT are re£ected in serum leptin levels.
At room temperature there was no increase due to treatment
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Fig. 2. Relative levels of leptin mRNA and serum leptin in C57Bl/6J mice treated with reserpine or vehicle (as described in Fig. 1). PCR experi-
ments using either leptin or actin primers were carried out separately. Cycle numbers for ampli¢cation of leptin cDNA were 28 for BAT and
22 for WAT. Actin PCR products were measured after 16 cycles for both tissues. PCR products were quanti¢ed by phosphorimaging and val-
ues for leptin product from each individual sample corrected for the signal obtained for the corresponding actin product. Each value was then
converted to a percentage of the mean from the vehicle treated animals. Serum leptin was measured using a leptin radioimmunoassay kit. Bars
show mean þ S.E.M. (n = 6^7 separate animals):*P6 0.05, no signi¢cant di¡erence.
Fig. 1. Southern blots of leptin and actin PCR products in C57Bl/6J mice treated with reserpine (n = 6) or vehicle (n = 6). Treated mice received
2 mg/kg reserpine i.p. at time 0, with a second dose of 2 mg/kg i.p. at 20 h. The mice were killed 24 h after the second injection. The ¢gure
shows sets of PCR products from tissues of individual mice, a: WAT, b: BAT.
B.A. Evans et al./FEBS Letters 444 (1999) 149^154 151
with propranolol or SR 59230A, whereas the combination of
antagonists appeared to increase serum leptin (non-signi¢cant,
P = 0.109). Cold-exposure for 4 h reduced serum leptin in mice
treated with any of vehicle, propranolol or SR 59230A. When
mice were pre-treated with propranolol plus SR 59230A, cold-
exposure no longer produced a signi¢cant decrease in serum
leptin (P = 0.29).
4. Discussion
This study provides evidence that out£ow from the SNS
stimulates both L3-ARs and the classical L1/L2-ARs. This hap-
pens to the greatest extent in BAT, which is highly innervated
by the SNS [22]. Our results indicate that even at room tem-
perature there is enough sympathetic tone to suppress expres-
sion of BAT leptin mRNA (Fig. 3). This suppression can be
alleviated by depleting sympathetic nerve terminals of cate-
cholamines with reserpine (Figs. 1 and 2) [21], or by blockade
of L-ARs. The e¡ects of SR 59230A and propranolol at room
temperature demonstrate that L3-ARs as well as classical L1/
L2-ARs mediate the response to basal sympathetic tone. Our
¢nding that the e¡ect of SR 59230A and propranolol in com-
bination is additive compared to the e¡ect of either single
antagonist could be interpreted in two ways. One is that the
responses mediated by L3-ARs occur via a di¡erent signalling
pathway to those mediated by L1/L2-ARs. This seems unlikely
as there is convincing evidence that all L-ARs are coupled
primarily to Gs in BAT [23,24]. Increases in cAMP modulate
leptin gene expression, as cAMP analogues and agents which
activate adenylate cyclase have been shown to reduce leptin
mRNA in vitro [5,14,16]. The amount of cAMP generated due
to basal stimulation of all three L-ARs clearly causes partial
suppression of leptin gene expression in BAT. When the
amount of cAMP is reduced due to receptor blockade, there
may be incremental increases in gene expression, reaching a
peak when all L-ARs are blocked.
When the SNS is stimulated due to cold-exposure, the large
increase in sympathetic out£ow would result in substantial
increases in cAMP generation [25]. Under these conditions
blockade of either L3-ARs or L1/L2-ARs alone is insu⁄cient
to reverse the cAMP-dependent suppression of leptin gene
expression. It is only when all three L-ARs are blocked that
the cold-induced increase in cAMP is prevented and leptin
mRNA remains at the same level as in the corresponding
animals held at room temperature.
Our ¢nding that propranolol plus SR 59230A prevents the
decrease in leptin mRNA also suggests that no other receptors
contribute substantially to the response to cold-exposure in
BAT. This is interesting given that K-ARs are possible candi-
dates for modulation of leptin synthesis. K1-ARs are present
in BAT, and activation of these receptors is coupled to a
stimulation of oxygen consumption [26]. K1A-ARs in the
BAT of Sprague-Dawley rats have been shown to be up-regu-
lated by cold-exposure (4‡C, 4 days) and infusion of the L3-
AR agonist CL 316243, both of which down-regulate leptin
synthesis [27]. Furthermore, activation of K1-ARs potentiates
the thermogenic response by synergistically activating aden-
ylate cyclase thereby increasing cAMP [28]. Further studies
using K1A-AR antagonists would be worthwhile to investigate
whether these receptors do play any role in regulating BAT
leptin synthesis. Another receptor which appears to play a
role in BAT oxygen consumption is the putative L4-AR [29],
which mediates a maximal response to the agonist CGP 12177
in both wild-type and L3-AR knock-out mice. However CGP
12177 has been shown to have L1-AR agonist properties in
cells expressing this receptor [30], so that the existence of the
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Fig. 3. Relative levels of leptin mRNA and serum leptin in C57Bl/
6J mice. Animals were injected i.p. with vehicle, propranolol (1.5
mg/kg), SR 59230A (1.5 mg/kg) or a combination of both antago-
nists at the same doses. After 15 min at 22‡C, the mice were left at
22‡C (open bars) or placed at 4‡C (¢lled bars) for 4 h. PCR experi-
ments using either leptin or actin primers were carried out sepa-
rately. Cycle numbers for ampli¢cation of leptin cDNA were 28 for
BAT and 22 for WAT. Actin PCR products were measured after 16
cycles for both tissues. PCR products were quanti¢ed by phosphor-
imaging and values for leptin product from each individual sample
corrected for the signal obtained for the corresponding actin prod-
uct. Each value was then converted to a percentage of the mean
from the vehicle treated animals left at 22‡C. Serum leptin was
measured using a leptin radioimmunoassay kit. Bars show mean þ
S.E.M. (n = 5^10 separate animals):*P6 0.05, e¡ect of L-antagonists
versus saline in mice held at 22‡C:VP6 0.05, mice at 4‡C versus
22‡C for a given drug treatment.
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L4-AR and its possible contribution to the regulation of leptin
synthesis remain uncon¢rmed.
Although leptin mRNA is abundant in cultured brown adi-
pocytes [5], leptin protein is undetectable in UCP-1 expressing
cells in vivo [4]. Instead leptin is present in white adipocytes
found within BAT depots of lean mice. We addressed directly
the relative abundance of leptin mRNA in BAT and WAT,
¢nding that for a ¢xed amount of total RNA the level in BAT
is only 2.7% of that found in WAT. Due to the large size of
white adipocytes, however, the yield of total RNA per wet
weight of tissue is 7-fold higher for BAT (865 þ 104 Wg/g,
n = 12) than for WAT (123 þ 9 Wg/g, n = 12). Taking this into
account the level of leptin mRNA for a given weight of BAT
would be 19% of that in WAT. Our study provides evidence
that even when BAT leptin mRNA is increased 5-fold (by
treatment of mice at room temperature with propranolol
plus SR 59230A), there is not a corresponding large increase
in serum leptin levels. The data shown in Fig. 2 and 3 indicate
that serum leptin essentially re£ects expression in WAT. This
is consistent with the relatively low body content of BAT
compared to WAT [17].
Activation of the SNS by acute cold-exposure reduced lep-
tin synthesis by 10-fold in BAT but only by 2-fold in WAT.
This e¡ect is much less marked than that seen by Trayhurn et
al. [9], who demonstrated that even after 2 h of cold-exposure
of mice, leptin mRNA was undetectable in WAT. The di¡er-
ence between the two studies may re£ect the conditions of
cold-exposure, or a di¡erence between the C57BL/6 strain
and the ‘Aston’ variety used by Trayhurn and coworkers.
Moinat et al. [10] found that exposure of male Sprague-Daw-
ley rats to 6‡C for 24 h had no e¡ect on leptin mRNA in
WAT although leptin expression was reduced signi¢cantly in
BAT. Again the di¡erent animal and the time and conditions
of cold-exposure may have in£uenced the results obtained.
In mice, the observed reduction in WAT leptin mRNA with
cold-exposure may be due to activation of the SNS or in-
creased circulating catecholamines. Our data do not distin-
guish clearly between these two possibilities. It had previously
been supposed that WAT is poorly innervated by the SNS,
with nerve terminals localised mainly in the proximity of
blood vessels [31]. However, 4 h cold-exposure of rats has
been shown to increase noradrenaline turnover by 3-fold in
WAT compared to 5-fold in BAT [32], indicating signi¢cant
sympathetic activity in WAT. Similarly, fasting appears to
selectively activate sympathetic stimulation to WAT whilst
decreasing activity in BAT [33]. In our study, sympathetic
blockade due to reserpine treatment caused a small but non-
signi¢cant increase in WAT leptin mRNA (Fig. 2). In mice
held at room temperature, separate blockade of L1/L2-ARs or
L3-ARs using propranolol or SR 59230A produced no change,
but the combination of antagonists caused a 1.8-fold increase
in leptin mRNA (Fig. 3). It is interesting to compare these
results with those of Rayner and coworkers [11], who found a
3-fold increase in leptin mRNA 10 h after treatment of mice
with KMPT. This agent inhibits noradrenaline synthesis in
sympathetic nerve terminals, but may also cause depletion
of circulating adrenaline [11]. Taken together, the data are
consistent with a chronic suppression of WAT leptin expres-
sion at room temperature caused partly by basal sympathetic
tone and partly by adrenaline. Under conditions of acute
cold-exposure, there may be increases in circulating adrenaline
as well as elevated sympathetic activity. Whichever mecha-
nism operates in cold-exposed mice, blockade of all three L-
ARs is clearly necessary to prevent the decrease in WAT
leptin mRNA.
In conclusion, we have shown that agents which modulate
sympathetic activity and responsiveness alter leptin gene ex-
pression primarily in BAT, and to a lesser extent in WAT.
This directly con¢rms the hypothesis that the SNS regulates
leptin synthesis in tissues that receive sympathetic innervation.
Importantly, responses to basal and stimulated sympathetic
activity in BAT and WAT are mediated by both L3-ARs
and classical L1/L2-ARs. WAT is the primary source of circu-
lating leptin, despite large increases in BAT leptin mRNA
following reserpine or L-AR antagonist treatment.
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